305 related articles for article (PubMed ID: 32323152)
1. The Role of VPS35 in the Pathobiology of Parkinson's Disease.
Sassone J; Reale C; Dati G; Regoni M; Pellecchia MT; Garavaglia B
Cell Mol Neurobiol; 2021 Mar; 41(2):199-227. PubMed ID: 32323152
[TBL] [Abstract][Full Text] [Related]
2. VPS35, the Retromer Complex and Parkinson's Disease.
Williams ET; Chen X; Moore DJ
J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
[TBL] [Abstract][Full Text] [Related]
3. An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex.
Macías-Calvio V; Fuentealba LM; Marzolo MP
J Neurosci Res; 2021 Jan; 99(1):163-179. PubMed ID: 32633426
[TBL] [Abstract][Full Text] [Related]
4. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.
Williams ET; Glauser L; Tsika E; Jiang H; Islam S; Moore DJ
Hum Mol Genet; 2018 Sep; 27(18):3189-3205. PubMed ID: 29893854
[TBL] [Abstract][Full Text] [Related]
5. VPS35 and retromer dysfunction in Parkinson's disease.
Rowlands J; Moore DJ
Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
[TBL] [Abstract][Full Text] [Related]
7. VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease.
Chen X; Tsika E; Levine N; Moore DJ
Mol Neurodegener; 2023 Aug; 18(1):51. PubMed ID: 37542299
[TBL] [Abstract][Full Text] [Related]
8. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.
Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC
J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease-linked
Chen X; Kordich JK; Williams ET; Levine N; Cole-Strauss A; Marshall L; Labrie V; Ma J; Lipton JW; Moore DJ
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5765-5774. PubMed ID: 30842285
[TBL] [Abstract][Full Text] [Related]
10. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N.
Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ
Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646
[TBL] [Abstract][Full Text] [Related]
11. VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology.
Cutillo G; Simon DK; Eleuteri S
Neurobiol Dis; 2020 Nov; 145():105056. PubMed ID: 32853677
[TBL] [Abstract][Full Text] [Related]
12. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila.
Inoshita T; Arano T; Hosaka Y; Meng H; Umezaki Y; Kosugi S; Morimoto T; Koike M; Chang HY; Imai Y; Hattori N
Hum Mol Genet; 2017 Aug; 26(15):2933-2948. PubMed ID: 28482024
[TBL] [Abstract][Full Text] [Related]
13. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin.
Malik BR; Godena VK; Whitworth AJ
Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041
[TBL] [Abstract][Full Text] [Related]
14. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
15. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model.
Chiu CC; Weng YH; Huang YZ; Chen RS; Liu YC; Yeh TH; Lu CS; Lin YW; Chen YJ; Hsu CC; Chiu CH; Wang YT; Chen WS; Liu SY; Wang HL
Cell Death Dis; 2020 Nov; 11(11):1018. PubMed ID: 33257649
[TBL] [Abstract][Full Text] [Related]
16. VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function.
Tang FL; Liu W; Hu JX; Erion JR; Ye J; Mei L; Xiong WC
Cell Rep; 2015 Sep; 12(10):1631-43. PubMed ID: 26321632
[TBL] [Abstract][Full Text] [Related]
17. VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2.
Yun SP; Kim H; Ham S; Kwon SH; Lee GH; Shin JH; Lee SH; Ko HS; Lee Y
Cell Death Dis; 2017 Apr; 8(4):e2741. PubMed ID: 28383562
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of
Sargent D; Moore DJ
Int Rev Mov Disord; 2021; 2():221-244. PubMed ID: 35497708
[TBL] [Abstract][Full Text] [Related]
19. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
Williams ET; Chen X; Otero PA; Moore DJ
Neurobiol Dis; 2022 Aug; 170():105768. PubMed ID: 35588987
[TBL] [Abstract][Full Text] [Related]
20. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.
Miura E; Hasegawa T; Konno M; Suzuki M; Sugeno N; Fujikake N; Geisler S; Tabuchi M; Oshima R; Kikuchi A; Baba T; Wada K; Nagai Y; Takeda A; Aoki M
Neurobiol Dis; 2014 Nov; 71():1-13. PubMed ID: 25107340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
